Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy.
Cell therapy
Cytokine
GVL
Innate immune cells
NK cell
γδ T-cells
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
08
09
2022
revised:
18
10
2022
accepted:
20
10
2022
entrez:
3
12
2022
pubmed:
4
12
2022
medline:
7
12
2022
Statut:
ppublish
Résumé
Innate immune cells [Natural killer (NK) and gamma-delta (γδ) T-cells] have the advantage of mediating graft versus leukemia (GVL) without graft versus host disease (GVHD). Therefore, the infusion of activated innate immune cells post allogenic hematopoietic stem transplant (AHSCT) is a promising adoptive immunotherapy strategy for relapsed and/or refractory myeloid malignancies. Microbead depletion of T-cells and B-cells has been used as a graft manipulation method to prevent GVHD post haploidentical AHSCT. These grafts are enriched for NK and γδ T-cell receptor (TCR
Identifiants
pubmed: 36461582
pii: S1567-5769(22)00871-2
doi: 10.1016/j.intimp.2022.109387
pii:
doi:
Substances chimiques
Cytokines
0
Interleukin-12
187348-17-0
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109387Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Todd Fehniger is an inventor on patent/patent applications (15/983,275, 62/963,971, and PCT/US2019/060005) licensed to Wugen Inc. and held/submitted by Washington University that cover aspects of ML NK cell biology. This results in potential royalties to T.F., and Washington University from Wugen Inc.T.F. has equity, research funding, consulting, and royalty interest in Wugen Inc. John DiPersio (Chief of Oncology) also has equity and royalty interest in Wugen.T.F. reports researching funding from HCW Biologics Inc., ImmunityBio, Wugen, and the NIH during the conduct of the study. T.F. also reports consulting for Affimed and Kiadis, Nkarta, Nektar, Takeda; and advises (equity interest) Indapta and OrcaBio. The rest of the authors have no interest to declare.